PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Cocrystal Pharma licences coronavirus drug candidates

Cocrystal Pharma has signed an agreement with Kansas State University Research Foundation (KSURF) for rights to preclinical compounds to treat coronavirus infection.

As part of the deal, the company also acquired exclusive, royalty-bearing right and licence to broad-spectrum antiviral compounds for norovirus treatment.

Cocrystal plans to progress the licensed compounds through research and development, including preclinical and clinical testing.

Cocrystal Pharma president Dr Sam Lee said: “This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the Covid-19 coronavirus and norovirus.

“There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that.”

The company’s technology is designed to produce a 3D structure of inhibitor complexes. This will help find new binding sites.

Cocrystal said that the technology was used to develop compounds that can selectively act on enzymes required for viral replication.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026